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Abstract
Background: Bacillus (B.) anthracis, the causal agent of anthrax, is effectively controlled by the Sterne live spore
vaccine (34F2) in animals. However, live spore vaccines are not suitable for simultaneous vaccination and antibiotic
treatment of animals being at risk of infection in an outbreak situation. Non-living vaccines could close this gap.
Results: In this study a combination of recombinant protective antigen and recombinant Bacillus collagen-like
antigen (rBclA) with or without formalin inactivated spores (FIS), targeted at raising an immune response against
both the toxins and the spore of B. anthracis, was tested for immunogenicity and protectiveness in goats. Two
groups of goats received from local farmers of the Kars region of Turkey were immunized thrice in three weeks
intervals and challenged together with non-vaccinated controls with virulent B. anthracis, four weeks after last
immunization. In spite of low or none measurable toxin neutralizing antibodies and a surprisingly low immune
response to the rBclA, 80% of the goats receiving the complete vaccine were protected against a lethal challenge.
Moreover, the course of antibody responses indicates that a two-step vaccination schedule could be sufficient for
protection.
Conclusion: The combination of recombinant protein antigens and FIS induces a protective immune response in
goats. The non-living nature of this vaccine would allow for a concomitant antibiotic treatment and vaccination
procedure. Further studies should clarify how this vaccine candidate performs in a post infection scenario
controlled by antibiotics.
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Background
Anthrax was one of the first bacterial diseases to be
controlled by vaccination. Starting with the famous
vaccination of sheep conducted at Pouilly-le-Fort,
France, by Louis Pasteur [1] his duplex vaccine became
widely used for cattle and sheep in Europe and South
America for about 50 years. It was, however, Max
Sterne’s live-spore vaccine [2] which in the long run be-
came the world’s most used live vaccine against anthrax
in the veterinary field [3]. It remains the veterinary vac-
cine in use in most countries encountering anthrax [4].
Sterne’s own trials with his vaccine [5, 6] had shown
effectiveness in diminishing outbreaks in South Africa
over the period 1925 to 1941. Nevertheless, while
proving effective in controlling anthrax worldwide over
the last 75 years, usage of the Sterne live spore vaccine
poses a number of problems. These include problems
related to the standardization of vaccine production and
avoidance of batch to batch variation in content and
immunogenicity, and the residual virulence known from
several laboratory species and livestock [2, 7–9], in
particular goats [3]. More importantly, especially for use
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in livestock and endangered wild species, the live vaccine
has been noted to prevent development of vaccine
induced antibodies when administered concomitantly
with an antibiotic in small laboratory rodents [10, 11].
The simultaneous antibiotic treatment and vaccination
would be of great importance for control of an outbreak
situation where the possible infection of livestock or wild
animals needs to be prevented after the activity of the
antibiotic has ceased. This concept has led to the
approval of a human vaccine (AVA, (BioThraxR), Emer-
gent BioSolutions) for a post-exposure scenario in
humans where antibiotics may be administered for up to
60 days [12]. In animals, the risk for infections by spores
originally present in or newly shed to the environment
by early victims of an outbreak is even much higher, as
one-shot treatments with long-lasting antibiotics gener-
ally do not protect for more than 14 days.
So far non-living alternatives are not available for
veterinary use, contrary to the licensed acellular human
vaccines AVA and AVP whose main immunological
ingredient is the so-called protective antigen (PA; see
reviews in [13–16]). However these are imposed with
limitations of their own like an extensive immunization
schedule, batch to batch variations in the content and
concentration of the antigens [17], and species-specific var-
iations in the protective capacity [18–22]. Thus the search
for more defined recombinant protein antigens analogous
to the licensed acellular human vaccines is still ongoing.
Varying results have been published in laboratory ani-
mal models (reviewed in 13) with purified PA prepara-
tions and recombinant PA (rPA). Results indicated that
vaccines solely based on the toxin derived antigens,
mainly PA, are less protective than live-spore vaccines
against virulent isolates of B. anthracis [7, 23–29]. Spore
vaccines constructed from toxigenic, non-encapsulated
strains have repeatedly demonstrated the capacity to
confer protection in mice and guinea pigs against
challenge with virulent B. anthracis [7, 9, 23, 24, 30, 31].
Better protection by live spore vaccines compared to
AVA or AVP has been attributed to improved stimula-
tion of the cellular or cell mediated immune response by
both spore and vegetative cell components [7, 8, 23, 32].
Brahmbhatt et al. [33] showed a protective effect of an
exosporium derived antigen, Bacillus collagen-like anti-
gen (BclA), when added to suboptimal amounts of PA in
a combination vaccine. This supported the results of
Hahn et al. [34] that showed the protection afforded by
a combination of rPA and rBclA encoding plasmids was
significantly better than protection provided by vaccin-
ation with the single components. More recently it was
shown that other spore derived antigens [27, 29, 35–37],
surface layer proteins [28, 38] or inactivated full spore
preparation such as FIS [39–41] can add to the protect-
ive efficacy of PA-based vaccines.
The PA-induced immune response is highly dependent
on the adjuvant used [19, 20]. In recent trials a lipopep-
tide adjuvant (LP), already validated in other contexts
[42–47], was compared with alhydrogel (Ah) in mice
and rabbits. Animals immunized with rPA and LP had
significantly higher antibody (IgG2a) titers than those
given rPA and Ah. When NMRI mice were challenged
subcutaneously with B. anthracis Ames spores the rPA/
LP immunized group survived significantly better than
both the negative controls and the rPA/Ah immunized
group, whereas rabbits were completely protected. None
of the animals showed clinical side effects with this
adjuvant [48].
As early as in 1946 Gladstone [49] recognized the
potential of a non-cellular vaccine against anthrax and
tested a culture filtrate of B. anthracis in several labora-
tory species and sheep. Experiments in the 1950s in
cattle, sheep, and pigs demonstrated the potential pro-
tectiveness of such a cell-free vaccine [50, 51], though
the interpretation of these trials was always hampered by
the inability to find a fully lethal dose with the challenge
strains used. To the best of our knowledge there have
been no further studies aimed at protecting livestock
animals from a virulent infection with B. anthracis by a
non-living vaccine since these early experiments.
Our study investigated the protective immune re-
sponse induced by a combination of recombinant
proteins with or without FIS in goats. This species was
selected given the extremely high susceptibility of goats
and their economic and social importance in many arid
or semi-arid areas of the world. A threefold vaccination
with a non-living vaccine comprising of rPA, rBclA and
FIS as the relevant antigens in combination with LP
adjuvant revealed 80% survival after a parenteral lethal
challenge with spores of B. anthracis. This indicates the
high potential of such vaccines as either a supplement or
even alternative to living spore vaccines when (i) vaccin-
ation is desirable to prevent the re-activation of an
outbreak after the initial antibiotic treatment or (ii)
when other non-living components are used in so-called
combination vaccines to immunize simultaneously
against both B. anthracis and a different pathogen. Such
combination vaccines are often used concomitantly with
antibiotics in the veterinary practice.
Methods
Animals
Goats were purchased from local farmers and comprised
of a phenotypically heterogeneous group of both males
and females of ages around 1 year, belonging to the
breed of Caucasian goats. Animals were sourced from
farms not affected by anthrax and with no anthrax
vaccine history in the last 5 years. All animals were
tested for anti-PA antibodies by ELISA and only animals
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considered negative were enrolled. Initially 25 goats were
held in one flock on a fenced pasture throughout the
vaccination. To allow for acclimatization the goats were
held at the site of the experiment for approximately
1 month prior to the start of the vaccination. All animals
were treated with Ivermectin (7 mg, s. c.) and mineral
supplement (Depomin, 10 ml orally per day, for 3 days)
and the health status was monitored by local veterinar-
ians. Two vaccine groups of 10 goats each (groups A
and B) and one unvaccinated negative control of 5 goats
(group NegCTL) were selected at random from the flock
to make up the experimental groups. During the chal-
lenge period groups of animals were held in separate
concrete barns equipped with water basins and racks
containing hay. Hay was provided ad libitum. At the end
of the trials barns and any non-burnable materials were
disinfected by spraying with 10% formaldehyde solution.
Carcasses and contaminated materials were incinerated.
Two animals of group A and one animal in group
NegCTL were lost during the time of vaccination but
before challenge (Table 1) due to reasons unrelated to
the vaccination procedure (two predations and one un-
known loss). The immunological data of these animals
were part of the evaluation.
Recombinant proteins
Escherichia coli BL21-CodonPlus-RIL cells (Stratagene,
La Jolla, CA) harboring the plasmid pREP 4 and pQE-30
(both Qiagen, Venlo, Netherland) encoding either rPA83
or rBclA coupled to a HIS-tag were grown and purified
as described previously [34]. Briefly, bacterial inoccula were
grown in antibiotic supplemented Standard medium I
(Roth, Karlsruhe, Germany). Upon reaching OD600nm of
0.6, protein production was induced with IPTG (Roth,
Karlsruhe, Germany). After incubation for 3 h at 37 °C
shaking cultures were lysed and proteins purified on a
HiTrap Sepharose column loaded with nickel(II)sulfate
(Sigma-Aldrich, Taufkirchen, Germany) via FPLC with
Äktaprime plus (GE Healthcare, Freiburg, Germany). After
dialysis onto 5 mM HEPES-buffer (Roth, Karlsruhe,
Germany) and quality assessment via SDS-page, protein
yield was established via Bicinchoninsäure test (Interchim,
Montlucon, France). Proteins used for ELISA received no
further treatment while proteins used for vaccination were
tested for endotoxin (ET) yield using the Limulus
Amoebocyte Lysate Endochrome-K test kit (Charles River,
Wilmington, MA) according to the manufactures’s instruc-
tions. Endotoxin removal was performed via EndoTrap blue
endotoxin removal system (Hyglos, Bernried, Germany) for
proteins with ET values more than 50 ng/kg body weight.
Formalin inactivated spores (FIS)
Sterne vaccine strain 34F2 spores (strain collection of
the University of Hohenheim) suspended in 0.9% NaCl
containing 0.1% gelatin were pelleted, then re-suspended
in PBS with 4% formalin and incubated at 37 °C over-
night. The suspension was centrifuged (4000 x g) four
times and re-suspended in 0.9% NaCl and 0.1% gelatin
with the last pellet re-suspended in endotoxin free PBS.
Sterility of 1 aliquot of the preparation was confirmed
on blood agar after neutralization of formalin with 1
volume of a solution containing 20 g/L histidine at room
temperature for 30 min.
Lipopeptide adjuvant
A lipopeptide adjuvant comprising Pam3Cys-SKKKK, a
TLR2/1 activator admixed with Pam3Cys conjugated to
the promiscuitive T-helper-cell epitope of the sperm
whale myoglobin SFISEAIIHVLHSRHPG [46, 47, 52]
was purchased from EMC Microcollections GmbH,
Germany.
Serology
All sera were tested individually for IgG antibodies
against the respective antigens rPA83, rBclA, and FIS in
the ELISA. IgM titers against rBclA and FIS were
assessed with pooled group sera from each sampling
point. The ELISA tests were performed as described
earlier [53]. Briefly 96-well Maxisorp plates (Sigma-
Aldrich, Taufkirchen, Germany) were coated with
0.5 μg antigen or respectively 108 cfu FIS per well in
coating buffer (8.4 g/L NaHCO3, 3.56 g/L Na2CO3)
over night. Sera were titrated on the plate in dupli-
cates using a serial log2 dilution with a starting con-
centration of 1:100. Controls included an equivalently
titrated goat serum positive for all antigen tested, as
well as point measurements (concentration 1:100) of
unvaccinated goat sera as a negative control. The sec-
ondary antibody rabbit anti-goat IgG HRP (Thermo
Fischer, Waltham, MA USA) was used at a dilution of
1:6000. Endpoint titers were developed with ABTS
(Roche, Mannheim, Germany) and defined as the
reciprocal of the highest serum dilution that resulted
in an OD414nm greater than 0.1.
Toxin-neutralizing assay (TNA) was performed as
published earlier [53] to qualitatively assess the ability of
antibodies generated to neutralize lethal toxin. Briefly,
heat inactivated individual sera were serially diluted in 8
log2 steps with a starting dilution of 1:50 on sterile 96
well plates (BD Biosciences, Heidelberg, Germany)
seeded with 105 J774 A.1 macrophages per well. Lethal
toxin (LF) was added at concentration of 500 ng/mL PA
and 100 ng/mL LF (List Biological Laboratories, Campbell,
CA, USA) and survival of macrophages was visualized
through MTT (5 mg/mL, Alfa Aesar, Karsruhe, Germany),
which is degraded by living cells to a measurable
(OD540nm) colour compound. The neutralization titer
(NT) corresponds to the inverse serum dilution at which
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the macrophage survival yielded 50% (NT50). ELISA titers
and NT50 were estimated using the Sigma Plot regression
wizard (4-parameter sigmoid regression curve).
Bacillus anthracis challenge strain
The virulent B. anthracis strain was isolated from the
spleen of a deceased bovine in the Kars region (strain K-
136, collection of the Department of Microbiology,
Faculty of Veterinary Medicine of the Kafkas University,
Turkey) and identified as described earlier [54]. Spores
were prepared as described in the WHO guidelines
“Anthrax in humans and animals” [4]. The presence of
both virulence plasmids pX01 and pX02 was tested by
PCR [4] from 10 single colonies randomly picked from
an overnight culture of the spore suspension on blood
agar. The virulence of the challenge strain was con-
firmed in BALB/c mice at Erciyes University Hakan
Cetinsaya Animal Experimentation Laboratory, Kayseri/
Turkey. For this, two groups of 2 mice were challenged
with 625 or respectively 1250 spores given s. c. in the
back. Death occurred within 68 h after the lethal
challenge and was verified through re-isolation of the
challenge strain from heart and lung tissue.
Immunizations and challenge
Goats of group A received a vaccine formulation com-
prising of 500 μg LP adjuvant, 75 μg rPA83 and 75 μg
rBclA per dose and group B goats received the same
formulation as A with the addition of 108 FIS per dose.
The 75 μg of recombinant proteins was a 25-fold in-
crease in PA that is present in a single dose of the
human vaccine AVA [55]. The spore dose was as
published for studies with mice and guinea pigs [39].
Group NegCTL served as an unvaccinated negative con-
trol without any injections. The groups were vaccinated
three times with 3 week intervals by subcutaneous
injection into the upper thigh of the hind leg with 1 mL
of vaccine (components diluted in 1 mL of endotoxin
free PBS). Blood samples were collected before each
immunization, right before and 14 days after challenge
from survivors (Fig. 1). All animals were challenged with
approximately 1000 spores at one time, except for two
randomly chosen members of group NegCTL (96,163
and kesik kulak) that were challenged before the rest of
the groups to establish the virulence of the spore
suspension prepared. Re-counting colony forming units
on blood agar plates revealed a number of 1027 spores
for the two negative controls challenged first and 918
spores for the other goats.
To assess the health status of the challenged goats the
general behaviour was checked and rectal temperature
was measured at least twice daily for 2 weeks after the
challenge. In cases of temperatures of ≥40 °C a blood
smear to determine the presence of encapsulated bacilli
in the blood was made [55]. Animals with negative blood
smears were monitored more frequently. Positive
animals were treated with 1 mL/25 kg body weight
Dipenisol (penicillin/streptomycin formulation, Bayer,
Leverkusen). The day of treatment was recorded as
“time of death” for the analysis of protectiveness. The
animal trials were approved by the Ethic Committee of
Animal Experimentation of the Erciyes University, No.
13/01, decision date 09.01.2013.
Statistics
Titer values for all four traits were transformed using a
logarithmic transformation, as residuals visually indicate
clearly increasing variances for larger expected values.
These data were then analyzed using a mixed model
assuming fixed effects for groups and time points and
their interactions. Furthermore, the model accounts for
repeated measures taken from each goat. Repeated
measures can be modelled by an unstructured variance
covariance matrix for observations from one goat, but
for all traits fitting a random goat effect and a week-
specific error variance increased model fit measured by
the Akaike information criterion (AIC). Values under
the detection limit were replaced by the halved value of
the detection level on the transformed scale. If all obser-
vations from one time point or one group were under
the detection level, the variance for these observations is
zero. To avoid underestimation of variances, we dropped
these observations and present means for them as under
detection level in the results section. A Tukey tests
accounting for multiple testing were performed only
after finding differences for a factor via F-Test. A letter
display was used were means with identical letters were
not significant different from each other. Additionally, in
case of non-significant interactions between group and
time point simple means were calculated, but not used
for testing. Predicted means were back transformed for
presentation only. Standard errors were back trans-
formed using the delta method. As titer values could
only be measured from surviving goats, means from the
last time point depend on the surviving of goats. For
those titers animal effects were correlated for the traits
anti-rPA83 and NT50 using a bivariate model. To elabor-
ate survival time the log rank test was employed using
data from all treated goats. Multiple comparison was
done using the adjustment by Tukey. For all statistical
evaluation a P-value of 0.05 was considered significant.
All analysis were done using the procedures PROC
MIXED and PROC LIFETEST of the SAS system.
Results
Anti-rPA-IgG titer
Titers of NegCTL group remained below the detection
threshold (< 100) throughout the study. The F-tests
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indicated differences between time points, but titers of
groups A and B show a similar development over time
(P = 0.47) and means were not significantly different
(P = 0.20). Mean anti-rPA83 titers increased significantly
in both group A and B after the first and second vaccin-
ation (P = 0.0001) but decreased after the 3rd vaccin-
ation (P = 0.0051). Mean titers of goats surviving the
challenge remained either nearly unchanged or raised
strongly compared to values after second and third
vaccination, leading to high variations within the groups
(Fig. 2 and Additional file 1: Table S1).
Toxin neutralization titer (NT50)
Sera of group NegCTL as well as sera of all goats before
the first immunization remained below the detection
limit (NT50 ≤ 50). The F-tests indicated differences be-
tween time points, but titers of groups A and B show a
similar development over time (P = 0.81) and means
were not significantly different (P = 0.25). After the first
immunization only individual goats of groups A and B
developed weak NT50 whereas the mean titers across
groups A and B increased significantly (p = 0.0023) after
the second immunization. In line with the tendency
observed for anti-rPA83 IgG, the third immunization
resulted in significant though lower mean titers
(P = 0.0028) (Figs. 2 and 3, week 10/11). NT50 of goats
surviving the challenge were highly variable (Fig. 3 and
Additional file 1: Table S2). Animal showing high values
for anti-rPA83 IgG also show high NT50 values
(r = 0.956).
Fig. 2 Anti-recombinant PA (rPA) ELISA titers. Displayed are IgG-antibody-values for individual animals as well as predicted means and standard
deviations for group A (rBclA + rPA83), B (rBclA + rPA83 + FIS) and NegCTL (unvaccinated negative control) on all sampling points measured via
indirect ELISA against rPA83. Values below the detection limit (<100) were given an arbitrary value of 10. Individual values are given as symbols
specific for each group (group A - triangle, group B - square and group NegCTL - circle). Mean values are given in the form of bar charts in the
background and standard deviations as positive values above the bars. Mean values were analyzed for statistical differences with P ≤ 0.05 as
indicated by lower case letters for comparing time points above the respective bars. As there was no significant difference (P > 0.20) between
group A and B for any sampling point concerning the anti-rPA83 IgG antibody titers, letters were displayed across both groups. Mean values with
identical letters were not significant different from each other. Means from group NegCTL were always under the detection limit and therefore
not included in the letter display. FIS: Formalin inactivated spores; rBcLA: Recombinant Bacillus collagen-like antigen; rPA: Recombinant
protective antigen
Fig. 1 Timeline of the vaccination and challenge schedule. Dashed arrows indicate blood sampling; dotted arrows indicate vaccination time
points and continuous arrows indicate the application of the challenge dose; Arrow’s lengths indicate schedule of the relevant groups (A-C);
† indicates death of individual goats unrelated to the experimental set up within the indicated time frame; In week 10 only 2 individuals of
group NegCTL (unvaccinated negative control) were bled and challenged to verify the functionality of the challenge set up, the remainder of
group C was challenged and bled in week 11 together with group A (rBclA + rPA83), and B (rBclA + rPA83 + FIS). FIS: Formalin inactivated
spores; rBcLA: Recombinant Bacillus collagen-like antigen; rPA: Recombinant protective antigen
Koehler et al. BMC Veterinary Research  (2017) 13:220 Page 5 of 11
Anti-rBclA-IgG titer
The F-tests indicated a significant interaction term, thus
different development of titers over time in different
groups. The mean titers of group B slightly increased
after the first and second immunization (P = 0.0101 and
P = 0.0078) but differ significantly only in week 6 from
the negative control group (Fig. 4 and Additional file 1:
Table S3).
Anti-FIS-IgG titer
Again, F-tests indicated a significant interaction term,
thus different development of titers over time in differ-
ent groups. The mean titer of group B was significantly
increased after the first (P < 0.0001) and second
immunization (P = 0.0027) and stayed nearly constant
after the third immunization and challenge (P = 0.1573,
P = 0.4273). Titers from the NegCTL group were
constant over time. Titers from group A, where FIS was
not constituent of the vaccine formulation, remained
nearly unchanged compared to serum before vaccination
(Fig. 5 and Additional file 1: Table S4). Pooled group
sera of every sampling point tested negative for IgM
antibodies against rBclA and FIS (data not shown).
Challenge
In Fig. 6 the time to death curves are plotted, taking only
full days into consideration. Two animals of group A got
antibiotic treatment after a positive blood smear on days
3 and 9, respectively, according to the end point rules of
this experiment. These animals were considered fatally
infected and the day of intervention was taken for calcu-
lation of the death curve. Using the test for multiple
comparisons group B shows a significant better survival
than the negative control, with 8 out of 10 survivors
(P = 0.0015) while group A with 4 out of 8 survivors did
not (P = 0.2895). The difference in survival rate between
group A and B is not significant (P = 0.4614) using the
test approach described above. This test approach simul-
taneously used data from all goats. Note that using three
two-sample log rank tests with a Bonferroni adjustment
for multiple testing here showed significant increased
survival rate for both groups A and B as compared to
the unvaccinated negative group (NegCTL).
Discussion
Living spore vaccines, currently used as one of the most
important measures for controlling anthrax in animals,
are not suitable for simultaneous antibiotic treatment
and vaccination. This scenario is relevant in veterinary
practice when vaccination is desirable to prevent the
re-activation of an outbreak after the initial antibiotic
treatment or when other non-living components are
used in so-called combination vaccines to immunize
simultaneously against both B. anthracis and a different
pathogen.
Fig. 3 Toxin neutralization assay (TNA)-titers. Displayed are toxin-neutralizing titers for individual animals as well as predicted means and standard
deviations for group A (rBclA + rPA83), B (rBclA + rPA83 + FIS) and NegCTL (unvaccinated negative control) on all sampling points. Values below
the detection limit (<50) were given an arbitrary value of . Individual values are given as symbols specific for each group (group A - triangle,
group B - square and group NegCTL - circle). Means are given in the form of bar charts in the background and standard deviations as positive
values above the bars. Results were analyzed for statistical differences with P ≤ 0.05 indicated by lower case letters for comparing time points
and upper case letters for comparing groups above the respective bars. Mean values of different time points with identical lower case letters were
not significant different from each other. Mean values of different groups with identical upper case letters were not significant different from each
other. As there was no significant difference (P > 0.25) between group A and B for any sampling point concerning the toxin-neutralizing titers,
letters were displayed across both groups. Mean values with identical letters were not significant different from each other. Means from group
NegCTL and before immunization were always under the detection limit and therefore not included in the letter display. FIS: Formalin inactivated
spores; rBcLA: Recombinant Bacillus collagen-like antigen; rPA: Recombinant protective antigen
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Fig. 4 Anti-rBclA ELISA titers. Displayed are IgG antibody-values for individual animals as well as predicted means and standard deviations for
group A (rBclA + rPA83), B (rBclA + rPA83 + FIS) and NegCTL (unvaccinated negative control) on all sampling points measured via indirect ELISA
against rBclA. Values below the detection limit (<100) were given an arbitrary value of 10. Individual values are given as symbols specific for each
group (group A - triangle, group B - square and group NegCTL - circle). Means are given in the form of bar charts in the background and
standard deviations as positive values above the bars. Results were analyzed for statistical differences with P ≤ 0.05 indicated by lower case letters
for comparing time points and upper case letters for comparing groups above the respective bars. Mean values of different time points with
identical lower case letters were not significant different from each other. Mean values of different groups with identical upper case letters were
not significant different from each other. Inter-group comparisons showed a significantly elevated mean IgG titer against rBclA for group B as
compared to group NegCTL in week 6 only. FIS: Formalin inactivated spores; rBcLA: Recombinant Bacillus collagen-like antigen; rPA: Recombinant
protective antigen
Fig. 5 Anti-FIS (formalin inactivated spores) ELISA titers. Displayed are IgG antibody-values for individual animals as well as predicted means and
their standard deviations for group A (rBclA + rPA83), B (rBclA + rPA83 + FIS) and NegCTL (unvaccinated negative control) on all sampling points
measured via indirect ELISA against FIS (formalin inactivated spores). Values below the detection limit (<100) were given an arbitrary value of 10
for better display. Individual values are given as symbols specific for each group (group A - triangle, group B - square and group NegCTL - circle).
Means are given in the form of bar charts in the background and standard deviations as positive values above the bars. Results were analyzed for
statistical differences with P ≤ 0.05 indicated by lower case letters for comparing time points and upper case letters for comparing groups above
the respective bars. Mean values of different time points with identical lower case letters were not significant different from each other. Mean
values of different groups with identical upper case letters were not significant different from each other. Inter-group comparisons showed
significantly elevated IgG titers for group B as compared to group A against FIS for all sampling points with the exception of week 0. FIS: Formalin
inactivated spores; rBcLA: Recombinant Bacillus collagen-like antigen; rPA: Recombinant protective antigen
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A growing body of data from vaccinations of labora-
tory animals show the superiority of vaccines supposed
to elicit protective immune responses against both the
action of the toxins and the replication of the bacterium.
We sought to know whether an appropriate non-living
combination vaccine could protect one of the most
susceptible species of livestock, goats, against a lethal
challenge with B. anthracis. This study demonstrated
that goats were protected by a combination of recom-
binant peptides with or without FIS from a lethal B.
anthracis challenge.
Based on promising results from earlier vaccination
experiments in mice [56], goats were immunized three
times at 3-week intervals with rPA and rBclA without
(group A) or plus B. anthracis 34F2 strain derived FIS
(group B) adjuvanted by a lipopeptide. This robust
vaccination regimen was chosen in an “all or nothing”
approach to ensure that in this pioneering experiment
even a minimal protectiveness would be verifiable. The
challenge with ~1000 spores of a fully virulent strain of
B. anthracis revealed 50% (4/8) and 80% (8/10) survival
for the 14 days monitoring period in group A and B, re-
spectively, while all animals (4/4) of the negative control
died within 5 days. According to the Tukey test for
multiple comparisons only group B showed a significant
protection in comparison to the negative control. This
result falls in line with the observations made earlier
where a combination of rPA83 and different concentra-
tions of FIS in guinea pigs and several mice strains re-
sulted in full protection [39, 40] whereas the components
given in single did not. ELISA and TNA titers measured
after each vaccination indicate that a two-step vaccination
could be sufficient for protection as titers were higher
after second vaccination than after third (Figs. 2, 3). This
needs to be further investigated to determine if a two-step
vaccination will protect target animals as well and to com-
pare the protectiveness in different livestock animals to
those of the current Sterne live spore vaccine (SLSV). In a
previous trial on the long-term protectiveness of the SLSV
in goats [57] a 100% survival from lethal challenge was
only achieved when goats were freshly boostered. The
single application of SLSV resulted in 60% (6 weeks post
vaccination) and 80% (62 weeks post vaccination) survival.
While the protectiveness of the threefold vaccination
schedule conducted here with the non-living vaccine looks
comparable to a single vaccination with SLSV anti-PA
and TNA-titers were equal or higher with the latter
at 4–6 weeks after vaccination compared to the peak
titers (week 6) with the non-living vaccine. However,
the titers of both anti-PA and TNA were fairly com-
parable right before challenge. Interestingly, anti-FIS
titers were much lower after a single vaccination with
SLSV (<1/10) compared to our group B titers but in-
creased comparably after a second vaccination with
living spores. Taken in mind the role of an anti-spore
immune response the high anti-FIS titers may have
contributed to the higher survival seen in group B.
Some animals showed measurable, but low ELISA ti-
ters against rPA83, rBclA and FIS before immunization.
This has been observed in other trials before [57] and
Fig. 6 Survival data. Displayed are survival data of goats immunized with protein component vaccines with or without FIS (formalin inactivated
spores) and challenged with fully virulent wild type strain Bacillus anthracis K-136. Survival was monitored up to 15 days. Significance was tested
via a log-rank test. P-values are as compared to the unvaccinated animals if not indicated otherwise. The time of death was either the day the
animal was found dead or the day of antibiotic treatment, as was the case for 2 goats of group A. The time points of their antibiotic treatment
are labelled with * in the figure
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can be attributed to unspecific reactivity, as the animals
utilized in this study had no historical vaccination back-
ground and were not connected to any anthrax outbreak.
Furthermore, the background titers of unvaccinated ani-
mals did not change significantly over time and conveyed
no protection. Because of this we focused our statistical
evaluation on the progressive change in titers over time
and between groups clearly showing a vaccine effect in
terms of seroconversion and survival in the vaccinated
animals. Of note, two animals in group A and B showed
no increase in anti-rPA and TNA titers after the survival
of the challenge as compared to before the challenge hint-
ing at a sterile immunity [58].
As the exosporium is the outermost surface of a B.
anthracis spore, it has been the focus of numerous novel
vaccination approaches by several laboratories. BclA
forms the hair-like extensions protruding from the
exosporium membrane [59, 60]. It has been shown to be
immunodominant [61] and adds to protectiveness of PA
based vaccines [33, 34, 56]. Goats injected with a protein
formulation of rPA83, rBclA and lipopeptide (group A)
showed little to no increase in ELISA titers using either
rBclA or FIS as the antigen. Goats supplementary
injected with FIS (group B) showed a strong increase in
anti-FIS IgG titers but still an only marginal increase in
titers against rBclA. Given the previously described re-
sults from mouse experiments the low responsiveness of
goats to either the recombinant or FIS-derived BclA was
unexpected. Interestingly, these results are in line with
serological data from a study in goats vaccinated with
the commercial Sterne spore vaccine. Vaccinates also
showed no change in anti-rBclA IgG titers over the
course of a year as compared to titers before the vaccin-
ation while anti-FIS IgG titers increased strongly after
the first and again after a booster immunization with the
Sterne spore vaccine [57]. It has been stated that the
main antibody response against BclA is directed against
the proteinaceous parts of the native protein [62] and
several reports have shown the immunogenic and pro-
tective capacity of a non-glycosylated rBclA [32–34, 56].
However, we cannot completely rule out that goats in
group B may have elicited antibodies against the carbo-
hydrate moieties of the glycosylated FIS-derived BclA
which were not detectable using rBclA as the antigen in
our ELISA. If so, such antibodies might have added to
the better protection in group B and immunogenic
oligosaccharide side chains of BclA may be considered
part of future non-living vaccines, too. Taken together
these results support the previously described notion
[27, 29] that BclA, albeit highly immunogenic, might not
be the only or even main relevant antigen from B.
anthracis spores. Vergis et al. [29] observed an even bet-
ter survival rate in mice challenged with Ames spores
after immunization with a ΔBclA strain of the anthracis-
like B. cereus G9241. The authors explained these
surprising results with observations by Cybulski et al.
[36] and Basu et al. [63], the latter demonstrating that
the removal of the exosporium from a spore enhances
the cytokine response in macrophages while the exospo-
rium itself is inert in this regard. More recently, Wang
et al. [64] implicated BclA in impairing antibody
responses and protection against lethal infection of mice
through inhibition of complement. The results of our
study indicate that BclA might not only partially mask
recognition of important antigens beneath the exospo-
rium, but is in addition poorly immunogenic in goats as
compared to mice and rabbits. If this has implications
concerning the high susceptibility of goats against an in-
fection with B. anthracis, needs further investigation.
Conclusions
The results of our study indicate the potential of an anti-
genic mixture eliciting an immune response against both
the toxins and the spore components of B. anthracis to
protect the extremely susceptible goat from a lethal
infection with B. anthracis. The non-living nature of this
vaccine would allow for a concomitant antibiotic treat-
ment and vaccination procedure. Data from serological
studies in goats support the robustness of immunogen-
icity of this vaccine also when administered in combin-
ation with long-term antibiotics (unpublished). Further
studies will clarify how this vaccine candidate performs
in a post infection scenario controlled by antibiotics.
Additional file
Additional file 1: Supporting tables. Table S1. Anti-rPA83 IgG titers.
Table S2. TNA titers. Table S3. Anti-rBclA IgG titers. Table S4. Anti-FIS
IgG titers. (XLSX 24 kb)
Abbreviations
Ah: Alhydrogel; AVA: Anthrax Vaccine Adsorbed; AVP: Anthrax Vaccine
Precipitated; B: Bacillus; BclA: Bacillus collagen-like antigen; ELISA: Enzyme Linked
Immunosorbent Assay; ET: Endotoxin; FIS: Formalin Inactivated Spores;
FPLC: Fast protein liquid chromatography; HRP: Horseredish Peroxidase;
IgG: Immunoglobulin G; IgM: Immunoglobulin M; IPTG: Isopropyl-β-D-
thiogalactopyranosid; LF: Lethal Factor; LP: Lipopeptide; NegCTL: Negative
Control group; NT: Neutralization Titer; PA: Protective Antigen; PBS: Phosphate
Buffered Saline; PCR: Polymerase Chain Reaction; RBclA: Recombinant BclA;
rPA: Recombinant Protective Antigen; SDS: Sodium Dodecyl Sulfoxid;
SLSV: Sterne’s Live Spore Vaccine; TNA: Toxin Neutralization Assay
Acknowledgements
The authors would like to thank Peter Turnbull for his invaluable
consultations during all phases of the work. We are very grateful for the
technical assistance of Elisabeth Blaschke, Sabine Hoche and Mehmet Yetgin.
Funding
This work has been funded by Deutsche Forschungsgemeinschaft
(BE 2157/4–1).
Availability of data and materials
All data generated or analyzed during this study are included in this
published article and its Additional files.
Koehler et al. BMC Veterinary Research  (2017) 13:220 Page 9 of 11
Authors’ contributions
SMK was involved in every stage of planning, organizing and conducting the
study and in manuscript writing, in partial fulfillment of her PhD studies.
FB and OC characterized the challenge strain of B. anthracis at the Kars
University. HD and MD designed and carried out the mouse challenge study
under BSL-3 conditions. MS and SO were responsible for planning, organizing
and coordinating all the risk level 3 experiments at the Kars University,
particularly the vaccination and challenge trials, and were involved in data
collection and interpretation. FB, OC, and OCN were involved in the acquisition
and analysis of data from the goat trials. OCN additionally carried out part of
the immunoassays at the University of Pretoria. JM performed the statistical
analysis. All authors have been involved in drafting the manuscript or revising it
critically, have given final approval of the version to be published and agreed
to be accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the work are appropriately
investigated and resolved. HvH made substantial contributions to conception
and study design. WB at University of Hohenheim has been the project leader
and together with HvH from University of Pretoria was involved in every stage




Animal trials including mice and goats were approved by the Ethic





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Infectiology and Animal Hygiene, University of Hohenheim,
Institute of Animal Science, 70593 Stuttgart, Germany. 2Faculty of Veterinary
Medicine, Department of Microbiology, Kafkas University, 36300 Kars, Turkey.
3Faculty of Medicine, Department of Infectious Diseases, Erciyes University,
38039 Kayseri, Turkey. 4Institute for Crop Science, University of Hohenheim,
Biostatistical Unit, 70593 Stuttgart, Germany. 5Department of Veterinary
Tropical Diseases, University of Pretoria, Onderstepoort 0110, South Africa.
6Robert-Koch-Institut, 13353 Berlin, Germany. 7Africa Health Research
Institute, Durban 4013, South Africa.
Received: 13 December 2016 Accepted: 4 July 2017
References
1. Pasteur L. De l'atenuation des virus et de leur retour a la virulence. C Rend
Acad Sci. 1881;92:429–35.
2. Sterne M. The immunization of laboratory animals against anthrax.
Onderstepoort J Vet Sci Anim Indust. 1939;13:313–7.
3. Turnbull PCB. Anthrax vaccines: past, present and future. Vaccine.
1991;9:533–9.
4. Turnbull PCB. Anthrax in Humans and Animals. WHO Press, 4th ed Geneva;
2008.
5. Sterne M. The use of anthrax vaccines prepared from avirulent
(uncapsulated) variants of bacillus anthracis. Onderstepoort J Vet Sci Anim
Indust. 1939;13:307–12.
6. Sterne M, Nicol J, Lambrechts MC. The effect of large-scale active
immunisation against anthrax. J S Afr Vet Med Assoc. 1942;13:53–63.
7. Little SF, Knudson GB. Comparative efficacy of Bacillus anthracis live spore
vaccine and protective antigen vaccine against anthrax in the guinea pig.
Infect Immun. 1986;52:509–12.
8. Turnbull PCB, Broster MG, Carman JA, Manchee RJ, Melling J. Development
of antibodies to protective antigen and lethal factor components of anthrax
toxin in humans and guinea pigs and their relevance to protective
immunity. Infect Immun. 1986;52:356–63.
9. Ivins BE, Welkos SL, Knudson GB, Littl SF. Immunization against anthrax with
aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and
with recombinant strains of Bacillus subtilis that produce anthrax protective
antigen. Infect Immun. 1990;58:303–8.
10. Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA. Development of
novel vaccines against anthrax in man. J Biotechnol. 1996;44:155–60.
11. Webster A. Inhibiting effect of antibiotics on anthrax vaccination. Aust Vet J.
1973;49:545.
12. Ionin B, et al. Evaluation of Immunogenicity and Efficacy of Anthrax Vaccine
Adsorbed for Postexposure Prophylaxis. Clin Vaccine Immunol.
2013;20:1016–26.
13. Cybulski RJ Jr, Sanz P, O’Brien AD. Anthrax vaccination strategies. JMAM.
2009;30:490–502.
14. Baillie LWJ. Past, imminent and future human medical countermeasures for
anthrax. J Appl Microbiol. 2006;101:594–606.
15. Scorpio A, Blank TE, Day WA, Chabot DJ. Anthrax vaccines: Pasteur to the
present. Cell Mol Life Sci. 2006;63:2237–48.
16. Little SF. Anthrax vaccines. BioDrugs. 2005;19:233–45.
17. Turnbull PCB. Anthrax vaccines. In: Artenstein AW, editor. Vaccines: a
biography. Springer Verlag, London: Springer Verlag; 2010. p. 57–71.
18. Welkos SL, Friedlander AM. Comparative safety and efficacy against Bacillus
anthracis of protective antigen and live vaccines in mice. Microb Pathog.
1988;5:127–39.
19. Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. Immunization
against anthrax with Bacillus anthracis protective antigen combined with
adjuvants. Infect Immun. 1992;60:662–8.
20. Ivins B, Fellows PF, Pitt ML, Estep J, Farchaus JW, Friedlander AM, Gibbs PH.
Experimental anthrax vaccines: efficacy of adjuvants combined with
protective antigen against an aerosol Bacillus anthracis spore challenge in
guinea pigs. Vaccine. 1995;13:1779–84.
21. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF,
Anderson GW Jr, Gibbs PH, Friedlander AM. Comparative efficacy of
experimental anthrax vaccine candidates against inhalation anthrax in
rhesus macaques. Vaccine. 1998;16:1141–8.
22. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, Friedlander
AM. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus
macaques against challenge by Bacillus anthracis isolates of diverse
geographical origin. Vaccine. 2001;19:3241–7.
23. Ivins BE, Ezzell JW, Jemski J, Hedlund KW, Ristroph JD, Leppla SH.
Immunization studies with attenuated strains of bacillus anthracis. Infect
Immun. 1986;52:454–8.
24. Welkos SL, Friedlander AM. Pathogenesis and genetic control of resistance
to the Sterne strain of bacillus anthracis. Microb Pathog. 1988;4:53–69.
25. Cohen S, Mendelson I, Altboum Z, Kobiler D, Elhanany E, Bino T, Leitner M,
Inbar I, Rosenberg H, Gozes Y, Barak R, Fisher M, Kronman C, Velan B,
Shafferman A. Attenuated nontoxinogenic and nonencapsulated
recombinant Bacillus anthracis spore vaccines protect against anthrax.
Infect Immun. 2000;68:4549–58.
26. Rhie GE, Roehrl MH, Mourez M, Collier RJ, Mekalanos JJ, Wang JY. A dually
active anthrax vaccine that confers protection against both bacilli and
toxins. Proc Natl Acad Sci U S A. 2003;100:10925–30.
27. Cote CK, Kaatz L, Reinhardt J, Bozue J, Tobery SA, Bassett AD, Sanz P, Darnell
SC, Alem F, O’Brien AD, Welkos SL. Characterization of a multi-component
anthrax vaccine designed to target the initial stages of infections well as
toxaemia. J Med Microbiol. 2012;61:1380–92.
28. Uchida M, Harada T, Enkhtuya J, Kusumoto A, Kobayashi Y, Chiba S, Shyaka
A, Kawamoto K. Pro-tective effect of bacillus anthracis surface protein EA1
against anthrax in mice. Biochem Biophy Res Commun. 2012;421:323–8.
29. Vergis JM, Cote CK, Bozue J, Alem F, Ventura CL, Susan L, Welkos SL,
O’Briena AD. Immunization of mice with formalin-inactivatedspores from
avirulent Bacillus Cereus strains provides significant protection from
challenge with bacillus anthracis Ames. Clin Vaccine Immunol.
2013;20:56–65.
30. Klein NF, DeArmon IA Jr, Lincoln RE, Mahlnadt BG, Fernelius AL.
Immunological studies of anthrax. II. Levels of immunity against bacillus
anthracis obtained with protective antigen and live vaccine. J Immunol.
1962;88:15–9.
31. Brossier F, Weber-Levy M, Mock M, Sirard JC. Role of toxin functional
domains in anthrax pathogenesis. Infect Immun. 2000;68:1781–6.
Koehler et al. BMC Veterinary Research  (2017) 13:220 Page 10 of 11
32. Ivins BE, Welkos S. Recent advances in the development of an improved
humen anthrax vaccine. Eur J Epidemiol. 1988;4:12–9.
33. Brahmbhatt TN, Darnell SC, Carvalho HM, Sanz P, Kang TJ, Bull RL,
Rasmussen SB, Cross AS, O'Brien AD. Recombinant exosporium protein BclA
of bacillus anthracis is effective as a booster for mice primed with
suboptimal amounts of protective antigen. Infect Immun. 2007;75:5240–7.
34. Hahn UK, Böhm R, Beyer W. DNA vaccination against anthrax in mice –
combination of anti-spore and anti-toxin components. Vaccine.
2006;24:4569–71.
35. Cote CK, Bozue J, Moody KL, DiMezzo TL, Chapman CE, Welkos SL. Analysis
of a novel spore antigen in bacillus anthracis that contributes to spore
opsonization. Microbiology. 2008;154:619–32.
36. Cybulski RJ Jr, Sanz P, McDaniel D, Darnell S, Bull RL, O’Brien AD.
Recombinant bacillus anthracis spore proteins enhance protection of mice
primed with suboptimal amounts of protective antigen. Vaccine.
2008;26:4927–39.
37. Enkhtuya J, Kawamoto K, Kobayashi Y, Uchida I, Rana N, Makino S.
Significant passive protective effect against anthrax by antibody to bacillus
anthracis inactivated spores that lack two virulence plasmids. Microbiology.
2006;152:3103–10.
38. Baillie LWJ, Hebdon R, Flick-Smith H, Williamson D. Characterisation of the
immune response to the UK human anthrax vaccine. FEMS Immunol Med
Microbiol. 2003;36:83–6.
39. Brossier F, Levy M, Mock M. Anthrax spores make an essential contribution
to vaccine efficacy. Infect Immun. 2002;70:661–4.
40. Gauthier YP, Tournier JN, Paucod JC, Corre JP, Mock M, Goossens PL, Vidal
DR. Efficacy of a vaccine based on protective antigen and killed spores
against experimental inhalational anthrax. Infect Immun. 2009;77:1197–207.
41. Glomski IJ, Corre JP, Mock M, Goossens PL. Cutting edge: IFN-c-producing
CD4 T lymphocytes mediate spore induced immunity to capsulated bacillus
anthracis. J Immunol. 2007;178:2646–50.
42. Loleit M, Ihlenfeldt HG, Brünjes J, Jung G, Müller B, Hoffmann P, Bessler WG,
Pierres M, Haas G. Synthetic peptides coupled to the lipotripeptide P3CSS
induce in vivo B and T helper cell responses to HIV-1 reverse transcriptase.
Immunobiology. 1996;195:61–76.
43. Schild H, Deres K, Wiesmüller KH, Jung G, Rammensee HG. Efficiency of
peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T
cells. Eur J Immunol. 1991;21:2649–54.
44. Schlecht S, Wiesmüller K-H, Jung G, Bessler WG. Lipopeptide als natürliche
Adjuvantien für Impfstoffe aus Gram-negativen Bakterien.
Naturwissenschaften. 1993;80:9–17.
45. Wiesmüller KH, Jung G, Hess G. Novel low-molecular- weight synthetic
vaccine against foot-and-mouth disease containing a potent B-cell and
macrophage activator. Vaccine. 1989;7:29–33.
46. Wiesmüller KH, Fleckenstein B, Jung G. Peptide Vaccines and Peptide
Libraries. Biol Chem. 2001;382:571–9.
47. Mittenbühler K, vdEsche U, Heinevetter L, Bessler WG, Huber M.
Lipopeptides: adjuvanticity in conventional and genetic immunization.
FEMS Immunol Med Microbiol. 2003;15:193–200.
48. Beyer W, Hahn UK, Boehm R. Lipopeptide adjuvant versus aluminium
hydroxide in PA based vaccines. 5th International BACT-Conference. Abstract
book. 2005;P14:49.
49. Gladstone GP. Immunity to anthrax: protective antigen present in cell-free
culture filtrates. Br J Exp Pathol. 1946;27:394–418.
50. Schlingman AS, Devlin HB, Wright GG, Maine RJ, Manning MC. Immunizing
activity of alum-precipitated protective antigen of bacillus anthracis in
cattle, sheep, and swine. Am J Vet Res. 1956;4:256–61.
51. Jackson FC, Wright GG, Armstrong J. Immunization of cattle against
experimental anthrax with alum-precipitated protective antigen or spore
vaccine. Am J Vet Res. 1957;18:771–7.
52. Ghielmetti M, Reschner A, Zwicker M, Padovan E. Synthetic bacterial
lipopeptide analogs: structural requirements for adjuvanticity. Immunbiol.
2005;210:211–5.
53. Hahn UK, Alex M, Czerny CP, Boehm R, Beyer W. Protection of mice against
challenge with bacillus anthracis STI spores after DNA vaccination. Int J Med
Microbiol. 2004;294:35–44.
54. Buyuk F, Sahin M, Cooper C, Celebi O, Saglam AG, Baillie L, Celik E, Akca D,
Otluet S. The effect of prolonged storage on the virulence of isolates of
Bacillus anthracis obtained from environmental and animal sources in the
Kars Region of Turkey. FEMS Microbiol Lett. 2015;362:fnv102.
55. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL. The Anthrax Vaccine: Is it
safe? Does it work? In: Committee to Assess the Safety and Efficacy of the
Anthrax Vaccine. In: Medical Follow-Up Agency, Institute of Medicine;
2002. doi:10.17226/10310.
56. Köhler SM, Baillie LW, Beyer W. BclA and toxin antigens augment each other
to protect NMRI mice from lethal bacillus anthracis challenge. Vaccine.
2015;33:2771–7.
57. Ndumnego OC, Köhler S, Crafford J, van Heerden H, Beyer W. Comparative
analysis of the immunologic response and protective efficacy induced by
the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model.
Vet Immunol Immunop. 2016;178:14–21.
58. Hermanson G, et al. A cationic lipid-formulated plasmid DNA vaccine
confers sustained antibody-mediated protection against aerosolized anthrax
spores. Proc Natl Acad Sci U S A. 2004;101:13601–6.
59. Sylvestre P, Couture-Tosi E, Mock M. A collagen-like surface glycoprotein is a
structural component of the bacillus anthracis exosporium. Mol Microbiol.
2002;45:169–78.
60. Sylvestre P, Couture-Tosi E, Mock M. Polymorphism in the collagen-like
region of the bacillus anthracis BclA protein leads to variation in
Exosporium filament length. J Bacteriol. 2003;185:1555–63.
61. Steichen CT, Kearney JF, Turnbough CL. Characterization of the exosporium
basal layer protein BxpB of bacillus anthracis. J Bacteriol. 2005;187:5868–76.
62. Steichen C, Chen P, Kearney JF, Turnbough CL Jr. Identification of the
immunodominant protein and other proteins of the bacillus anthracis
exosporium. J Bacteriol. 2003;185:1903–10.
63. Basu S, Kang TJ, Chen WH, Fenton MJ, Baillie L, Hibbs S, Cross AS. Role of
bacillus anthracis spore structures in macrophage cytokine responses. Infect
Immun. 2007;75:2351–8.
64. Wang Y, Jenkins SA, Gu C, Shree A, Martinez-Moczygemba M, Herold J,
Botto M, Wetsel RA, Xu Y. Bacillus anthracis spore surface protein BclA
mediates complement factor H binding to spores and promotes spore
persistence. PLoS Pathog. 2016;12:e1005678.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Koehler et al. BMC Veterinary Research  (2017) 13:220 Page 11 of 11
